Daiichi Sankyo Company, Limited
Consolidated Financial Results for 2Q FY2026
Cumulative results for 2Q FY2026 show sales revenue up +19.7% YoY and operating income up +34.4% YoY. No revision to full-year forecast. Growth driven by key products ENHERTU and Tarlatamab. Reviewed and corrected CMO loss compensation items. Strengthening financial soundness and promoting operational excellence.
Key Figures
- Sales Revenue: 9,754 hundred million yen (Year-over-Year +19.7%)
- Operating Income: 1,442 hundred million yen (Year-over-Year +34.4%)
- Net Income Attributable to Owners of Parent: 1,308 hundred million yen (Year-over-Year +13.3%)
AI要約
Overview of Performance
Cumulative results through 2Q FY2026 showed a substantial increase in sales revenue versus the prior period, with improved cost ratios and foreign exchange effects leading to a significant rise in operating income. Supported by growth of core products ENHERTU® and Tarlatamab®, sales revenue has exceeded one trillion yen by the second quarter. The company targets record-high full-year sales revenue.
Outlook and Financial Measures
Consolidated earnings forecasts for FY2026 remain unchanged from the July announcement. Measures to enhance the reliability of financial reporting include additional reversals and corrective actions related to provisions for CMO loss compensation. The company aims to balance profit contribution and future growth investment through the promotion of operational excellence.
Sales Revenue Trend
Operating Income Trend
Forecast vs. Actual Comparison
Daiichi Sankyo Company, Limited
Company overview · Stock price · Financial data · All IR
